Azitra, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; it does not provide standalone fourth-quarter results. Azitra is an early-stage dermatology biopharmaceutical company and has not commenced commercial operations. Its limited revenue is primarily service revenue from its Bayer joint development agreement.
Business context and pipeline
Azitra develops engineered proteins and topical live biotherapeutics for skin diseases, using a proprietary library of approximately 1,500 bacterial strains, screening tools and genetic engineering technologies.
- ATR-12: Investigational topical live biotherapeutic for Netherton syndrome. The FDA cleared its IND in January 2023; trial operating activities began in December 2023. Initial safety results are expected in the second half of 2024.
- ATR-04: Candidate for EGFR-inhibitor-associated rash. The company planned to submit an IND by mid-2024 and, subject to FDA clearance, begin a Phase 1b trial in the fourth quarter of 2024.
- ATR-01: Engineered filaggrin protein candidate for ichthyosis vulgaris. Lead optimization and IND-enabling work were planned for 2024, with an IND filing targeted for the second half of 2025.
- Bayer collaboration: Bayer selected two strains for further development. Azitra delivered characterization data in the fourth quarter of 2023; Bayer has a 12-month option period to license the strains and related patent rights. No commercial license had been negotiated as of the report.
Financial results and liquidity
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Revenue | $686,000 | $284,000 | Up $402,000, or 142%; all reported revenue was related-party service revenue under the Bayer agreement. |
| General and administrative expense | $4.49 million | $3.64 million | Up 23%, mainly reflecting public-company costs. |
| Research and development expense | $3.81 million | $6.10 million | Down about 38%; management cited lower Netherton-program costs as it transitioned toward clinical work, reduced staffing and consultant use, partly offset by increased costs for other programs. |
| Operating loss | $7.62 million | $9.45 million | Improved by approximately $1.84 million. |
| Net loss | $11.28 million | $10.68 million | Loss widened by approximately $0.60 million, principally reflecting a larger noncash fair-value loss on convertible notes. |
| Net loss attributable to common shareholders | $12.64 million | $13.45 million | Improved by approximately $0.81 million; includes preferred-stock dividends. |
| Net loss per share, basic and diluted | $1.83 | $12.74 | Per-share comparison is affected by the 2023 IPO, preferred-stock and note conversions, and increased weighted-average shares. |
| Net cash used in operating activities | $7.36 million | $8.35 million | Cash burn declined by approximately $0.99 million. |
| Cash used in investing activities | $0.32 million | $0.34 million | Primarily patent-related costs. |
| Cash provided by financing activities | $5.98 million | $4.13 million | Primarily IPO proceeds in 2023; convertible-note proceeds in 2022. |
At December 31, 2023, cash and cash equivalents were $1.80 million, total assets were $5.12 million, working capital was approximately $0.93 million, and accumulated deficit was $48.60 million. Total liabilities were $2.20 million. Convertible notes were $6.60 million at year-end 2022 and zero at year-end 2023 after conversion at the IPO; lease liabilities and a $35,453 warrant liability remained. No product sales or meaningful commercial revenue were reported.
The June 2023 IPO generated approximately $6.0 million in net proceeds. After year-end, Azitra completed a February 2024 offering of 16,667,000 shares at $0.30 per share, generating approximately $4.4 million net. Despite that financing, management said cash on hand was not expected to fund the proposed plan of operations for the next 12 months and that additional financing would be required.
Outlook, risks and unusual items
- Going concern: Management and the independent auditor cited substantial doubt about Azitra’s ability to continue as a going concern, due to recurring losses, operating cash outflows and dependence on additional financing. The audited statements contain no adjustments for the outcome of this uncertainty.
- Funding and dilution: Further equity, debt, licensing or partnership financing may be needed and may not be available on acceptable terms. Equity financing could materially dilute existing shareholders. The February 2024 offering substantially increased the share count.
- Development and regulatory risk: The pipeline is early-stage; preclinical results may not predict clinical outcomes, and clinical trials or regulatory approval may be delayed or unsuccessful. ATR-12’s trial is an early Phase 1b study; ATR-04 remained preclinical at the reporting date.
- Manufacturing and commercialization: Azitra relies on third parties for key materials and future commercial manufacturing, has no commercial sales and marketing organization, and lacks long-term commercial supply agreements.
- Unusual accounting items: A $3.63 million noncash loss from the change in fair value of convertible notes contributed to the 2023 net loss; the notes converted at the IPO. The company also recorded $351,360 of impairment for intangible assets and deferred patent costs, and $56,285 of income from forgiveness of accounts payable.
- Controls: Management concluded disclosure controls were ineffective at December 31, 2023 because of a material weakness involving inadequate segregation of accounting duties. Remediation was planned through increased accounting staffing; the auditor did not express an opinion on internal controls.
- Other risks: Competition, patent protection and potential infringement claims, dependence on key personnel and partners, reimbursement and drug-pricing changes, and volatile trading and NYSE American listing risks are highlighted. No material legal proceedings were reported.
Important facts for investors to verify
- Current cash balance, monthly cash burn and management’s financing plan and runway after the February 2024 offering.
- ATR-12 enrollment progress, trial timing and the expected second-half 2024 safety update.
- Whether ATR-04’s IND was submitted and cleared, and whether its clinical-trial timetable remains achievable.
- Whether Bayer exercised its option to license the selected strains and the potential economics of any resulting agreement.
- Progress in remediating the accounting segregation material weakness and whether controls are operating effectively.
- Updated share count and potential dilution from the February offering, underwriter warrant and outstanding equity awards.
- Reconciliation of reported financial metrics and program spending against subsequent filings; the filing describes R&D expense as down 37% in one narrative passage and 38% in its results table.